221 related articles for article (PubMed ID: 16312384)
21. New azoles as first line therapy for Paecilomyces lilacinus in transplant patients.
Garzoni C; Garbino J
Transpl Infect Dis; 2008 Apr; 10(2):149-50. PubMed ID: 18353095
[No Abstract] [Full Text] [Related]
22. Azole tolerance test: a bedside observation to enhance physical diagnosis of superficial fungal infection.
Schneiderman H; Kristof L
Conn Med; 2012 Feb; 76(2):124. PubMed ID: 22670369
[No Abstract] [Full Text] [Related]
23. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.
Billaud EM; Guillemain R; Berge M; Amrein C; Lefeuvre S; Louët AL; Boussaud V; Chevalier P
Med Mycol; 2010 Nov; 48 Suppl 1():S52-9. PubMed ID: 21067331
[TBL] [Abstract][Full Text] [Related]
24. Antifungal drugs.
Treat Guidel Med Lett; 2008 Jan; 6(65):1-8. PubMed ID: 18157085
[No Abstract] [Full Text] [Related]
25. Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients.
Gubbins PO
Curr Opin Infect Dis; 2007 Dec; 20(6):579-86. PubMed ID: 17975407
[TBL] [Abstract][Full Text] [Related]
26. Recent approaches to antifungal therapy for invasive mycoses.
Mathew BP; Nath M
ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067
[TBL] [Abstract][Full Text] [Related]
27. [Contribution of second-generation azoles in Candida spp. infections].
Lizasoain M; Díaz Pedroche C; Lumbreras C
Rev Esp Quimioter; 2004 Mar; 17(1):105-8. PubMed ID: 15201934
[No Abstract] [Full Text] [Related]
28. Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy.
Troke PF; Andrews RJ; Pye GW; Richardson K
Rev Infect Dis; 1990; 12 Suppl 3():S276-80. PubMed ID: 2184505
[TBL] [Abstract][Full Text] [Related]
29. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?
Hof H
Drug Resist Updat; 2008; 11(1-2):25-31. PubMed ID: 18325827
[TBL] [Abstract][Full Text] [Related]
30. PURLs: Yeast infection in pregnancy? Think twice about fluconazole.
Barzin A; Mounsey A
J Fam Pract; 2016 Sep; 65(9):624-6. PubMed ID: 27672689
[TBL] [Abstract][Full Text] [Related]
31. Treatment of endemic mycoses.
Vyas KS; Bariola JR; Bradsher RW
Expert Rev Respir Med; 2010 Feb; 4(1):85-95. PubMed ID: 20387295
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Brüggemann RJ; Alffenaar JW; Blijlevens NM; Billaud EM; Kosterink JG; Verweij PE; Burger DM
Clin Infect Dis; 2009 May; 48(10):1441-58. PubMed ID: 19361301
[TBL] [Abstract][Full Text] [Related]
33. Rational use of antifungal drugs in deep mycoses.
Fara GM
Prog Clin Biol Res; 1979; 35():195-202. PubMed ID: 538032
[No Abstract] [Full Text] [Related]
34. Azole therapy of clinical and experimental coccidioidomycosis.
Stevens DA; Clemons KV
Ann N Y Acad Sci; 2007 Sep; 1111():442-54. PubMed ID: 17344535
[TBL] [Abstract][Full Text] [Related]
35. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
36. New antifungal agents in pediatric practice.
Das S; Shivaprakash MR; Chakrabarti A
Indian Pediatr; 2009 Mar; 46(3):225-31. PubMed ID: 19346570
[TBL] [Abstract][Full Text] [Related]
37. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
Sheng C; Zhang W; Ji H; Zhang M; Song Y; Xu H; Zhu J; Miao Z; Jiang Q; Yao J; Zhou Y; Zhu J; Lü J
J Med Chem; 2006 Apr; 49(8):2512-25. PubMed ID: 16610794
[TBL] [Abstract][Full Text] [Related]
38. Antifungal agents: an overview. Part I.
Gupta AK; Sauder DN; Shear NH
J Am Acad Dermatol; 1994 May; 30(5 Pt 1):677-98; quiz 698-700. PubMed ID: 8176006
[TBL] [Abstract][Full Text] [Related]
39. Treatment options for invasive fungal infections.
Dodds Ashley ES
Pharmacotherapy; 2006 Jun; 26(6 Pt 2):55S-60S. PubMed ID: 16716123
[TBL] [Abstract][Full Text] [Related]
40. [Significant role of azole antifungal agents: focused on itraconazole].
Nishikawa T; Watanabe K
Jpn J Antibiot; 1995 Sep; 48(9):1033-50. PubMed ID: 7474328
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
